07 jun: USA/tendens: Kina og Spanien ventes at give stigninger
07 jun: Carlsberg: Ølsalget firedobles før EM-kamp
07-06-2012 14:57:00

PRESS RELEASE: Bayer HealthCare Unveils Advances in CT Contrast Dose Management(TM) Solutions

Bayer HealthCare Unveils Advances in CT Contrast Dose Management(TM) Solutions

Powerful New Certegra(R) Informatics Workstation launched at SIIM 2012

Intended for U.S. Media Only

PR Newswire

TARRYTOWN, N.Y., June 7, 2012

TARRYTOWN, N.Y., June 7, 2012 /PRNewswire/ -- Bayer Radiology & Interventional announced the introduction of the Certegra(R) Workstation, an informatics-driven, touch--screen hub that enables time savings and improved patient care through a powerful suite of CT Contrast Dose Management(TM) applications and a new P3T(R) 2.0 operating environment. The new Workstation will be presented at the annual meeting of the Society for Imaging Informatics in Medicine (SIIM) 2012 June 7 - 12 in Orlando, FL. Following the initial launch in the U.S. and Canada, the Workstation will be rolled out in phases in markets around the world.

The Workstation serves as a single interface for radiology technologists, enabling them to provide improved patient care from study set-up and preparation to administration of the patient's study. It will be the cornerstone of Bayer's industry-first[1] Contrast Dose Management solution and informatics platform. In establishing and uploading the patient's contrast-injection record, the Workstation imports patient data directly from the Modality Work List -- reducing manual entry errors to the patient record.

"Today's technology-driven CT suite demands timely access to reliable contrast-dose records throughout the chain of care," said Anthony Cinalli, vice president of the informatics business at Bayer Radiology & Interventional. "Enabling a single workflow-centralized interface, the Workstation allows for fewer clicks, less manual entry and greater control over the quality and consistency of patient care."

Interfacing with Medrad Stellant(R) CT injection systems, the Workstation's comprehensive suite of software options provides physicians and healthcare professionals instant access to real-time actionable CT contrast data captured at the point of care enabling benefits including:

-- Reduce sub-diagnostic studies, unnecessary rescans and associated

radiation exposure[2] [3],(P3T 2.0 for personalized CT abdominal, cardiac

and pulmonary angiography studies)

-- Enable more complete diagnostic decisions (PACS Outbound Interface)

-- Speed-up radiology report turnaround time and create greater study-volume

bandwidth (RIS and SR Outbound Interfaces)

-- Improve department performance by trending, reporting and analyzing

actionable data with pinpoint accuracy (Informatics Starter Package, and

the Data Analysis and Reporting Tool)

Bayer HealthCare will have the Certegra(R) Workstation on display at its booth at SIIM 2012 (booth #217 - 221).

About Bayer HealthCare

The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 17.2 billion (2011), is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare's aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,700 employees (Dec 31, 2011) and is represented in more than 100 countries. Find more information at www.bayerhealthcare.com.

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

[1] Reference on file.

[2] Presented at Society of Thoracic Radiology (2008) Poster Session; Christopher R. Deible, MD, PhD. Study supported by MEDRAD Inc.

[3] 510(k) FDA clearance number: K082905

SOURCE Bayer HealthCare

/CONTACT: Karen Sutherland, +1-973-487-2113, karen.sutherland@bayer.com or Alicia Cafardi, +1-724-940-8621, alicia.cafardi@bayer.com

/Web site: http://www.bayerhealthcare.com/

(END) Dow Jones Newswires

June 07, 2012 08:57 ET (12:57 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
27 nov
 
Hej alle sammen   Renten USA USA hæver renten d. 14. dec. med 0,25 %. Fed vil gerne have renten lidt..
59
02 dec
ZEAL
For en gangs skyld og kun denne ene gang svarer jeg dig.   Jeg anser dine indlæg omkring Zealand græ..
37
28 nov
ZEAL
Jeg kan altsaa umuligt tro at Goodwrench og Alpehue har succes paa at handle aktier.. Hvordan kan I ..
29
29 nov
ZEAL
...når de investerer i mindre virksomheder og så vil ud hurtigt uanset at selskabet har fremgang og ..
21
27 nov
BAVA
En måske lidt dramatisk overskrift, men jeg mener det for Bavarian Nordic, der kommer til at ske eks..
19
27 nov
OMXC20
Sæt skatten 25% ned på de lavest lønnede. Disse folk vil bruge pengene med det samme, glade for at h..
18
02 dec
ZEAL
Novo Nordisk og Zealand er nu med i den helt absolutte front i kombinations behandling af diabetes -..
16
29 nov
 
Følgende artikel giver et godt indblik i at ledende danske politikere har større interesser i at mel..
16
30 nov
FING-B
Jeg har tidligere været yderst kritisk indstillet til hvad Di.se med Richard Bråse har skrevet om FP..
15
30 nov
ZEAL
PLEASE EI, STOP NU I DET MINDSTE FOLK I OG SKRIVE DET SAMME OG DET SAMME PROVOKERENDE PIS DAG EFTER ..
14

Mærsk/Nykredit: Anbefaling løftes til "køb" og kursmål til 12.100 - NY

02-12-2016 15:30:03
Mærsk får løftet anbefalingen til "køb" fra "sælg" og kursmålet til 12.100 kr. fra 10.300 kr. af Nykredit efter torsdagens meddelelse om opkøbet af Hamburg Süd...

Aktier/middag: Mærsk i plus i ellers afventende marked op til nøgletal

02-12-2016 12:02:35
A.P. Møller-Mærsk får fortsat lidt medvind af torsdagens meddelelse om opkøbet af det tyske containerrederi Hamburg Süd. Samtidig stiger fragtraterne på contain..

Nyt dansk biotekselskab får starthjælp fra Novo Seeds

02-12-2016 10:41:51
Behandling af neuropatisk smerte er omdrejningspunktet for det nystiftede danske biotekselskab Hoba Therapeutics, der netop er blevet stiftet ved hjælp af et ka..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2016  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
3. december 2016 22:46:25
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20161129.2 - EUROWEB3 - 2016-12-03 22:46:25 - 2016-12-03 22:46:25 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x